Indication
- In combination with trametinib for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600 mutation who require systemic therapy.
- In combination with trametinib for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600 mutation who have received at least one prior radiation and/or chemotherapy treatment.
Medicine details
- Medicine name:
- dabrafenib (Finlee)
- SMC ID:
- SMC2667
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 09 September 2024
- SMC meeting date:
- 06 August 2024
- Patient group submission deadline:
- 03 June 2024